Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010

Background/purpose Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Graefe's archive for clinical and experimental ophthalmology Jg. 251; H. 11; S. 2499 - 2503
Hauptverfasser:	Cohen, Salomon Y., Dubois, Lise, Ayrault, Sandrine, Dourmad, Pauline, Delahaye-Mazza, Corinne, Fajnkuchen, Franck, Nghiem-Buffet, Sylvia, Quentel, Gabriel, Tadayoni, Ramin
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2013 Springer Nature B.V
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Exudates and Transudates Female Fluorescein Angiography Humans Intravitreal Injections Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab Retinal Disorders Retrospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology Exudative age-related macular degeneration Real-life retrospective study Ranibizumab
ISSN:	0721-832X, 1435-702X, 1435-702X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!